FORMULATION AND IN VITRO CHARACTERIZATION OF THE SOLID LIPID NANOPARTICLES OF NAFTOPIDIL FOR ENHANCING ORAL BIOAVAILABILITY

BHARTI GUPTA; RAHUL SHARMA

doi:10.22159/ajpcr.2023.v16i2.46465

Authors

BHARTI GUPTA Department of Pharmaceutics, Hindu College of Pharmacy, Sonipat 131001, Haryana, India. https://orcid.org/0000-0002-2921-178X
RAHUL SHARMA Department of Pharmaceutics, Hindu College of Pharmacy, Sonipat 131001, Haryana, India.

DOI:

https://doi.org/10.22159/ajpcr.2023.v16i2.46465

Keywords:

Naftopidil, Solid lipid nanoparticles, oral bioavailability, entrapment efficiency

Abstract

Objective: Naftopidil (NAF) is a selective alpha1-adrenergic receptor antagonist with a nearly 20% bioavailability due to poor aqueous solubility, permeability, and extensive first-pass metabolism. To improve the bioavailability of the NAF, the solid lipid nanoparticles (SLN) of NAF were prepared.

Methods: SLNs NAF were prepared using the solvent emulsification/evaporation method with excipients Compritol 888 ATO and Poloxamer 188. Formulation F10 shows better entrapment efficiency (EE) as compare to other formulations so, it has selected to optimize the particle size, zeta potential, surface morphology, Fourier transform infrared spectroscopy (FTIR), and in vitro drug release and stability studies were assessed.

Results: The results showed that NAF was successfully incorporated in SLN. Having EE of all formulations ranged from 56% to 88%, drug loading ranged from 17% to 20%, drug content ranged from 77% to 98%, particle size and zeta potential of F10 were 270.2 nm and 21.7 mV, respectively, and FTIR revealed no interaction between drug and lipid in the formulation. The release of NAF-SLNs increased significantly, reaching a maximum of 4.547–82.418% in pH 6.8 buffer, the release data were fitted into the Korsmeyer-Peppas model yielding the highest correlation coefficient (R2=0.916). The stability study revealed that the formulation stability and bioavailability might be improved.

Conclusion: It can be concluded that SLN could be effective nanoplatforms for increasing NAF oral bioavailability.

Downloads

Download data is not yet available.

References

Mannava MK, Dandela R, Tothadi S, Solomon KA, Nangia AK. Naftopidil molecular salts with improved dissolution and permeation. Cryst Growth Des 2020;20:3064-76. doi: 10.1021/acs.cgd.9b01689

Rahat I, Rizwanullah MD, Gilani SJ, Bin-Jummah MN, Imam SS, Kala C, et al. Thymoquinone loaded chitosan-solid lipid nanoparticles: Formulation optimization to oral bioavailability study. J Drug Deliv Sci Technol 2021;64:102565. doi: 10.1016/j.jddst.2021.102565

Trucillo P, Campardelli R. Production of solid lipid nanoparticles with a supercritical fluid assisted process. J Supercrit Fluids 2019;143:16-23. doi: 10.1016/j.supflu.2018.08.001

Reddy NR, Shariff A. Solid lipid nanoparticles, an advanced drug delivery system. Int J Pharm Sci Res 2013;4:161-71.

Olbrich C, Kayser O, Müller RH. Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)-effect of surfactants, storage time and crystallinity. Int J Pharm 2002;237:119-28. doi: 10.1016/ s0378-5173(02)00035-2, PMID 11955810

Başaran E, Demirel M, Sırmagül B, Yazan Y. Cyclosporine-a incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul 2010;27:37-47. doi: 10.3109/02652040902846883, PMID 19545226

Sznitowska M, Wolska E, Baranska H, Cal K, Pietkiewicz J. The effect of a lipid composition and a surfactant on the characteristics of the solid lipid microspheres and nanospheres (SLM and SLN). Eur J Pharm Biopharm 2017;110:24-30. doi: 10.1016/j.ejpb.2016.10.023, PMID 27815177

Hanumanaik M, Patel SK, Sree KR. Solid lipid nanoparticles; a review. Int J Pharm Sci Res 2013;4:928-40.

Dara T, Vatanara A, Meybodi MN, Vakilinezhad MA, Malvajerd SS, Vakhshiteh F, et al. Erythropoietin-loaded solid lipid nanoparticles: Preparation, optimization, and in vivo evaluation. Colloids Surf B Biointerfaces 2019;178:307-16. doi: 10.1016/j.colsurfb.2019.01.027, PMID 30878805

Wang L, Wang CY, Zhang Y, Fu HJ, Gao Y, Zhang KR. Preparation and characterization of solid lipid nanoparticles loaded with salmon calcitonin phospholipid complex. J Drug Deliv Sci Technol 2019;52:838-45. doi: 10.1016/j.jddst.2019.05.045

Cai S, Yang Q, Bagby TR, Forrest ML. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev 2011;63:901-8. doi: 10.1016/j.addr.2011.05.017, PMID 21712055

Choi JS, Ahn JB, Park JS. Amorphous multi-system of celecoxib improves its anti-inflammatory activity in vitro and oral absorption in rats. Int J Pharm 2019;555:135-45. doi: 10.1016/j.ijpharm.2018.11.050, PMID 30458259

Choi JS, Byeon JC, Park JS. Naftopidil-fumaric acid interaction in a solid dispersion system: Improving the dissolution rate and oral absorption of naftopidil in rats. Mater Sci Eng C Mater Biol Appl 2019;95:264-74. doi: 10.1016/j.msec.2018.10.089, PMID 30573249

Sohn JS, Kim JS, Choi JS. Development of a naftopidil-chitosan-based fumaric acid solid dispersion to improve the dissolution rate and stability of naftopidil. Int J Biol Macromol 2021;176:520-9. doi: 10.1016/j.ijbiomac.2021.02.096, PMID 33607140

Elagamy HI, Essa EA, Nouh AT, El Maghraby GM. Development and evaluation of rapidly dissolving buccal films of naftopidil: In vitro and in vivo evaluation. Drug Dev Ind Pharm 2019;45:1695-706. doi: 10.1080/03639045.2019.1656734, PMID 31418592

Elagamy HI, Nouh AT, Essa EA, El Maghraby GM. Preparation and evaluation of chewable tablets of naftopidil. Eur J Biomed Pharm Sci 2019;6:10-9.

Karthik T, Prasad AS, Bhrama RR. Formulation and evaluation of naftopidil immediate release tablets. Indo Am J Pharmacol Sci 2015;2:1441-52.

Diwan R, Ravi PR, Pathare NS, Aggarwal V. Pharmacodynamic, pharmacokinetic and physical characterization of cilnidipine loaded solid lipid nanoparticles for oral delivery optimized using the principles of design of experiments. Colloids Surf B Biointerfaces 2020;193:111073. doi: 10.1016/j.colsurfb.2020.111073, PMID 32388122

Adithya BP, Krishna R, Vijayalakshmi M, Kumar AR. Spectrophotometric estimation of naftopidil in bulk and dosage form. Int Res J Pharm App Sci 2012;2:26-30.

Bhalerao A, Chaudhari PP. Formulation of solid lipid nanoparticles of cilnidipine for the treatment of hypertension. J Drug Deliv Ther 2019;9:212-21. doi: 10.22270/jddt.v9i3.2849

Garg A, Singh S. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers. Colloids Surf B Biointerfaces 2011;87:280-8. doi: 10.1016/j.colsurfb.2011.05.030, PMID 21689909

Farsani PA, Mahjub R, Mohammadi M, Oliaei SS, Mahboobian MM. Development of perphenazine-loaded solid lipid nanoparticles: Statistical optimization and cytotoxicity studies. BioMed Res Int 2021;2021:6619195. doi: 10.1155/2021/6619195, PMID 33997026

Chatwal GR, Anand SK. Instrumental Methods of Chemical Analysis. 5th ed. Delhi: Himalaya Publishing House; 2002. p. 149-59.

Kushwaha AK, Vuddanda PR, Karunanidhi P, Singh SK, Singh S. Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability. BioMed Res Int 2013;2013:584549. doi: 10.1155/2013/584549, PMID 24228255

Ekambaram P, Sathali A. Formulation and evaluation of solid lipid nanoparticles of ramipril. J Young Pharm 2011;3:216-20.